Am J Cardiol: 外周动脉疾病合并冠状动脉疾病的患者,预后不良

2017-03-22 MedSci MedSci原创

目的:指南推荐药物治疗(GDMT)对有无冠状动脉疾病(CAD)外周动脉疾病(PAD)长期临床预后的影响。方法:从2006到2013,共有879跛行或严重肢体缺血(CLI)的患者在多学科的血管中心进行血管内介入诊断或治疗。在造影时评估是否应用GDMT,随访5年确定主要不良心脑血管事件(MACCE)和全因死亡率。应用Cox比例风险模型调整有无CAD患者的基线差异。结果:对阿司匹林、血管紧张素转换酶抑制

目的:指南推荐的药物治疗(GDMT)对有无冠状动脉疾病(CAD)患者的外周动脉疾病(PAD)长期临床预后的影响。

方法:从2006到2013,共有879跛行或严重肢体缺血(CLI)的患者在多学科的血管中心进行血管内介入诊断或治疗。在造影时评估是否根据GDMT进行治疗,对受试者随访5年确定主要不良心脑血管事件(MACCE)的发生和全因死亡率。应用Cox比例风险模型校正有无CAD患者,是否存在基线差异。

结果:阿司匹林、血管紧张素转换酶抑制剂或血管紧张素受体拮抗剂、他汀类药物的应用较高依从GDMT(P均≤0.002)的PAD且合并CAD患者5年未校正MACCE发生率(HR 1.7,95%CI 1.3-2.1,P = 0.0001)和全因死亡率(HR 1.86,95% CI 1.4~2.4,P = 0.0001)较高。校正基线合并症后,CAD的存在仍然是死亡率的独立危险因素(校正HR 1.35,95% CI 1.02~1.80,P = 0.04),但不是MACCE发生的独立危险因素(HR 1.24,95% CI 0.96~1.60,P = 0.10)。对CLI患者进行单独分析,合并CAD的患者与MACCE(校正HR 1.52,95% CI 1.14~2.03,P = 0.01)和死亡率(校正HR 1.64,95% CI 1.12~2.20,P = 0.006)升高显著相关。

结果:总之,尽管根据GDMT进行治疗, PAD合并CAD的患者术后随访5年总体死亡风险显著增加。合并CAD的CLI患者主要心血管事件和全因死亡率的发生均较高。

原文出处:

Chen DC, Singh GD, et al. Long-Term Comparative Outcomes of Patients With Peripheral Artery Disease With and Without Concomitant Coronary Artery Disease. Am J Cardiol. 2017 Jan 25.


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1781737, encodeId=243c1e81737e6, content=<a href='/topic/show?id=5db8409ed8' target=_blank style='color:#2F92EE;'>#Cardiol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4097, encryptionId=5db8409ed8, topicName=Cardiol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Sat Dec 23 01:42:00 CST 2017, time=2017-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252888, encodeId=574f1252888b6, content=<a href='/topic/show?id=463230886b8' target=_blank style='color:#2F92EE;'>#冠状动脉疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30886, encryptionId=463230886b8, topicName=冠状动脉疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Fri Mar 24 01:42:00 CST 2017, time=2017-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1488331, encodeId=6877148833155, content=<a href='/topic/show?id=b34f1001e187' target=_blank style='color:#2F92EE;'>#预后不良#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100171, encryptionId=b34f1001e187, topicName=预后不良)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b86b8414062, createdName=caoliehu, createdTime=Fri Mar 24 01:42:00 CST 2017, time=2017-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1593275, encodeId=e93d15932e57f, content=<a href='/topic/show?id=8d1342e95fa' target=_blank style='color:#2F92EE;'>#外周动脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42795, encryptionId=8d1342e95fa, topicName=外周动脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b27818121614, createdName=wujh_7312825, createdTime=Fri Mar 24 01:42:00 CST 2017, time=2017-03-24, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1781737, encodeId=243c1e81737e6, content=<a href='/topic/show?id=5db8409ed8' target=_blank style='color:#2F92EE;'>#Cardiol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4097, encryptionId=5db8409ed8, topicName=Cardiol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Sat Dec 23 01:42:00 CST 2017, time=2017-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252888, encodeId=574f1252888b6, content=<a href='/topic/show?id=463230886b8' target=_blank style='color:#2F92EE;'>#冠状动脉疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30886, encryptionId=463230886b8, topicName=冠状动脉疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Fri Mar 24 01:42:00 CST 2017, time=2017-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1488331, encodeId=6877148833155, content=<a href='/topic/show?id=b34f1001e187' target=_blank style='color:#2F92EE;'>#预后不良#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100171, encryptionId=b34f1001e187, topicName=预后不良)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b86b8414062, createdName=caoliehu, createdTime=Fri Mar 24 01:42:00 CST 2017, time=2017-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1593275, encodeId=e93d15932e57f, content=<a href='/topic/show?id=8d1342e95fa' target=_blank style='color:#2F92EE;'>#外周动脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42795, encryptionId=8d1342e95fa, topicName=外周动脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b27818121614, createdName=wujh_7312825, createdTime=Fri Mar 24 01:42:00 CST 2017, time=2017-03-24, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1781737, encodeId=243c1e81737e6, content=<a href='/topic/show?id=5db8409ed8' target=_blank style='color:#2F92EE;'>#Cardiol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4097, encryptionId=5db8409ed8, topicName=Cardiol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Sat Dec 23 01:42:00 CST 2017, time=2017-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252888, encodeId=574f1252888b6, content=<a href='/topic/show?id=463230886b8' target=_blank style='color:#2F92EE;'>#冠状动脉疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30886, encryptionId=463230886b8, topicName=冠状动脉疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Fri Mar 24 01:42:00 CST 2017, time=2017-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1488331, encodeId=6877148833155, content=<a href='/topic/show?id=b34f1001e187' target=_blank style='color:#2F92EE;'>#预后不良#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100171, encryptionId=b34f1001e187, topicName=预后不良)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b86b8414062, createdName=caoliehu, createdTime=Fri Mar 24 01:42:00 CST 2017, time=2017-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1593275, encodeId=e93d15932e57f, content=<a href='/topic/show?id=8d1342e95fa' target=_blank style='color:#2F92EE;'>#外周动脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42795, encryptionId=8d1342e95fa, topicName=外周动脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b27818121614, createdName=wujh_7312825, createdTime=Fri Mar 24 01:42:00 CST 2017, time=2017-03-24, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1781737, encodeId=243c1e81737e6, content=<a href='/topic/show?id=5db8409ed8' target=_blank style='color:#2F92EE;'>#Cardiol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4097, encryptionId=5db8409ed8, topicName=Cardiol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Sat Dec 23 01:42:00 CST 2017, time=2017-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252888, encodeId=574f1252888b6, content=<a href='/topic/show?id=463230886b8' target=_blank style='color:#2F92EE;'>#冠状动脉疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30886, encryptionId=463230886b8, topicName=冠状动脉疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Fri Mar 24 01:42:00 CST 2017, time=2017-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1488331, encodeId=6877148833155, content=<a href='/topic/show?id=b34f1001e187' target=_blank style='color:#2F92EE;'>#预后不良#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100171, encryptionId=b34f1001e187, topicName=预后不良)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b86b8414062, createdName=caoliehu, createdTime=Fri Mar 24 01:42:00 CST 2017, time=2017-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1593275, encodeId=e93d15932e57f, content=<a href='/topic/show?id=8d1342e95fa' target=_blank style='color:#2F92EE;'>#外周动脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42795, encryptionId=8d1342e95fa, topicName=外周动脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b27818121614, createdName=wujh_7312825, createdTime=Fri Mar 24 01:42:00 CST 2017, time=2017-03-24, status=1, ipAttribution=)]

相关资讯

Circ Res:外周动脉疾病自体细胞治疗的疗效如何?

虽然这项荟萃分析强调了需要更高质量的安慰剂对照试验,平衡可能不再被保证,因为自体细胞治疗具有调整难治性CLI自然病史的潜力。

PLoS One:伴有外周动脉疾病的心衰患者,卒中和死亡率较高

背景:伴有不同血管疾病的心脏衰竭患者,卒中和死亡风险研究较少。研究者进行了一项观察性研究,以评估不伴有房颤的心脏衰竭,存在外周动脉疾病(PAD)或心肌梗死(MI)患者,卒中和死亡的风险。方法:从丹麦全国登记记录中识别2000-2012年,诊断为无房颤的心衰患者。经过1年的随访,比较存在PAD,MI史或血管疾病史患者缺血性卒中和全因死亡的HR。结果:包括39357个心脏衰竭患者。与无血管疾病的心衰患

PAD患者福音!FDA批准Shockwave Medical新型声波气囊有条件上市

心血管疾病一直是威胁人类生命健康的最大敌人之一。由于人们生活和饮食习惯问题,许多患者会出现动脉腔变窄而血流放缓,从而出现一系列疾病症状。近年来以血管成形术为基础的气囊设备在这一疾病领域中发扬光大。最近,FDA批准了Shockwave Medical公司的最新型血管成形术气囊设备Lithoplasty有条件上市,用于治疗出现血管钙化的心血管疾病患者。这也是目前市场上首个能够治疗血管钙化的

NEJM:外周动脉疾病患者替卡格雷并不优于氯吡格雷

由此可见,对于有症状的外周动脉疾病患者,在减少心血管事件方面,替卡格雷并不优于氯吡格雷,而且两组患者的大出血发生率也相似。

JACC:替卡格雷可降低外周动脉疾病患者(曾患过心梗)的缺血性风险

在之前有过心肌梗死(MI)的患者中,外周动脉疾病(PAD)与缺血性和出血风险增加有关。这项研究评估了在PAD和之前有过MI的患者中,替卡格雷治疗对于主要心血管(CV)事件和重大不良肢体事件的疗效性和安全性。PEGASUS-TIMI54研究随机分配21162例之前有过MI(1〜3年)的患者接受替卡格雷90毫克每天两次,替卡格雷60毫克,每天两次,或安慰剂,所有都以低剂量阿司匹林为背景。是否有PAD的

JACC: 伴有心肌梗死的PAD患者,应用替卡格雷进行二级预防有效可行

背景:外周动脉疾病(PAD)与存在心肌梗死史(MI)患者较高的缺血和出血风险有关。目的:在PEGASUS-TIMI 54这一试验中,研究者评估存在心肌梗死史的PAD患者,应用替卡格雷治疗对主要心血管事件和不良的上肢事件的有效性和安全性。方法:PEGASUS-TIMI 54将21162名存在心肌梗死的患者随机分为,替卡格雷90 mg治疗组,60 mg治疗组或安慰剂组,所有患者都给予低剂量的阿司匹林。